Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

Source: 
Pharmaceutical Business Review
snippet: 


Xencor has dosed the first patient in a phase 1 clinical trial that will evaluate its bispecific antibody XmAb23104 for the treatment of advanced solid tumors.